← Search & browse all drugs
VARIOUS › THERAPEUTIC RADIOPHARMACEUTICALS › PAIN PALLIATION (BONE SEEKING AGENTS) › Various pain palliation radiopharmaceuticals
samarium (153Sm) lexidronam
V10BX02
Forms & Strengths
- Intravenous injection: 1,850 MBq/mL (50 mCi/mL) at calibration time
Adult Dosing
- Palliative treatment of bone pain: 37 MBq/kg (1 mCi/kg) administered via slow intravenous injection over 1 minute
Pediatric Dosing
- Safety and effectiveness in pediatric patients below the age of 18 years have not been established
Indications
- Palliative relief of bone pain in patients with confirmed osteoblastic bone metastases
Mechanism of Action
- Emits beta radiation and gamma photons; ethylenediaminetetramethylene phosphonate (EDTMP) chelates calcium and localizes in areas of bone turnover and osteoblastic metastases
Contraindications
- Known hypersensitivity to similar phosphonate compounds
- Pregnancy and lactation
- Severe bone marrow suppression unless clinically justified
Adverse Reactions
- Transient myelosuppression (leukopenia and thrombocytopenia nadir at 3-4 weeks)
- Bone pain flare shortly after administration
- Nausea and vomiting
- Allergic reactions
Drug Interactions
- Bone-seeking agents or treatments affecting calcium/bone metabolism may alter biodistribution
- Myelosuppressive chemotherapy or external beam radiation may increase risk of severe bone marrow suppression
Curated Content: Needs Vetting Before Put to Clinical Use